[ CAS No. 1041053-44-4 ]

Name: 1041053-44-4|Oxazol-2-ylmethanamine hydrochloride|98%
Brand: Ambeed
SKU: A260074
Rating: 94 (22 reviews)

{[proInfo.proName]} ,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

2D 3D

Structure of 1041053-44-4 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Bulk Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 100K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 1041053-44-4 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 1041053-44-4 ]

SDS Specification

Alternatived Products of [ 1041053-44-4 ]

Product Details of [ 1041053-44-4 ]

CAS No. :	1041053-44-4	MDL No. :	MFCD06738929
Formula :	C₄H₇ClN₂O	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	YMJMSYXLHSSGTP-UHFFFAOYSA-N
M.W :	134.56	Pubchem ID :	46912060
Synonyms :

Calculated chemistry of [ 1041053-44-4 ]

Physicochemical Properties

Num. heavy atoms :	8
Num. arom. heavy atoms :	5
Fraction Csp3 :	0.25
Num. rotatable bonds :	1
Num. H-bond acceptors :	3.0
Num. H-bond donors :	1.0
Molar Refractivity :	31.14
TPSA :	52.05 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	Yes
P-gp substrate :	No
CYP1A2 inhibitor :	No
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-7.1 cm/s

Lipophilicity

Log Po/w (iLOGP) :	0.0
Log Po/w (XLOGP3) :	0.03
Log Po/w (WLOGP) :	0.78
Log Po/w (MLOGP) :	-0.94
Log Po/w (SILICOS-IT) :	0.53
Consensus Log Po/w :	0.08

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	2.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-1.09
Solubility :	10.9 mg/ml ; 0.0813 mol/l
Class :	Very soluble
Log S (Ali) :	-0.68
Solubility :	28.4 mg/ml ; 0.211 mol/l
Class :	Very soluble
Log S (SILICOS-IT) :	-1.2
Solubility :	8.45 mg/ml ; 0.0628 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	0.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	1.91

Safety of [ 1041053-44-4 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P261-P305+P351+P338	UN#:	N/A
Hazard Statements:	H302-H315-H319-H335	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 1041053-44-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 1041053-44-4 ]

[ 1041053-44-4 ] Synthesis Path-Downstream 1~9

1
6'-(6-cyano-1-ethyl-1H-indol-3-ylmethyl)-4-methoxy-biphenyl-2,3'-dicarboxylic acid 2-benzyl ester [ No CAS ]
[ 1041053-44-4 ]
2'-(6-cyano-1-ethyl-1H-indol-3-ylmethyl)-4-methoxy-5'-[(oxazol-2-ylmethyl)-carbamoyl]-biphenyl-2-carboxylic acid [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
91%	With 4-methyl-morpholine; (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate; In DMF (N,N-dimethyl-formamide); at 20℃; for 72.0h;	Part A. 2'-(6-cyano-1-ethyl-1H-indol-3-ylmethyl)-4-methoxy-5'-[(oxazol-2-ylmethyl)-carbamoyl]-biphenyl-2-carboxylic acid A mixture of the compound of Example 15, Part F (75 mg, 0.138 mmol), <strong>[1041053-44-4]oxazol-2-yl-methylamine hydrochloride</strong> (28 mg, 0.208 mmol) NMM (0.012 mL, 1.10 mmol) and BOP reagent (76 mg, 0.172 mmol) in DMF (1 muL) was stirred at rt over 3 days. Reaction was worked up and product isolated as described for Example 15, Part G to provide the amide (78.3 mg, 91%). LC/MS m/z 625.3 (M+H)+.

Reference： [1]Patent: US2005/228000,2005,A1 .Location in patent: Page/Page column 27

2
[ 848144-43-4 ]
[ 1041053-44-4 ]
[ 76-05-1 ]
[ 1041053-42-2 ]

Yield	Reaction Conditions	Operation in experiment
17%		To a solution of 5-tert-butyl-2-methoxybenzoic acid (253 mg, 1 rnmol, prepared as in WO2005023761 ) in DCM/DMF (5 ml, 1 : 1 ), <strong>[1041053-44-4]oxazol-2-ylmethanamine hydrochloride</strong> (135 mg, 1 mmol), PyBOP (1.04 g, 2 mmol) and DIEA (0.87 ml, 5 mmol) were added. The resulting mixture was stirred at r.t. overnight. The DCM was evaporated and the resulting DMF solution was subjected to RP-HPLC (gradient: 40 to 99% AcN in H2O) to give the TFA-salt of the title compound (78 mg, 17%) as a yellow solid. (Calculated mass: 333.3, observed mass: 334.1 ).

Reference： [1]Patent: WO2008/89034,2008,A2 .Location in patent: Page/Page column 115

3
[ 1041053-44-4 ]
[ 105-36-2 ]
C₈H₁₂N₂O₃ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		A solution of <strong>[1041053-44-4]oxazol-2-ylmethanamine hydrochloride</strong> (83 mg, 0.60 mmol) in methanol (2 mL) and a 25% by weight sodium methoxide/methanol solution (0.137 mL) were added, followed by stirring at room temperature for 15 minutes. Then, insoluble matters were filtered off, and the solvent was evaporated under reduced pressure. The obtained residue was diluted with acetonitrile (4 mL), and potassium carbonate (83 mg, 0.60 mmol) was added thereto, followed by cooling to -10 C. to -15 C. Then, ethyl 2-bromoacetate (0.066 mL, 0.60 mmol) diluted with acetonitrile (1 mL) was added dropwise. The temperature was gradually raised to room temperature, and the mixture was stirred overnight. After insoluble matters were separated by filtration, the filtrate was concentrated under reduced pressure.

Reference： [1]Patent: US2016/46592,2016,A1 .Location in patent: Paragraph 0332

4
[ 1041053-44-4 ]
[ 927-68-4 ]
2-(oxazol-2-yl-methylamino)ethyl acetate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With potassium carbonate; In acetonitrile; at -15 - 20℃;	Oxazol-2-yl methane amine hydrochloride (69mg, 0.50mmol) in acetonitrile (3mL) solution of potassium carbonate (173mg, 1.25mmol) was cooled to -10 ~ -15 was added, and acetonitrile ( diluted with 1 mL) 2-bromoethyl acetate (0.055 mL, was added dropwise 0.50 mmol), it was slowly stirred overnight raised to room temperature. After filtering off the insoluble materials, by distilling off the solvent under reduced pressure to give the title compound without purification.

Reference： [1]Patent: JP2016/13983,2016,A .Location in patent: Paragraph 0078

5
[ 1041053-44-4 ]
2-chloro-4-((2-fluoro-6-(trifluoromethyl)benzyl)amino)quinazoline-8-carbonitrile [ No CAS ]
4-((2-fluoro-6-(trifluoromethyl)benzyl)amino)-2-((oxazol-2-ylmethyl)amino)quinazoline-8-carbonitrile [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
37%	With N-ethyl-N,N-diisopropylamine; In 1,4-dioxane; dimethyl sulfoxide; at 100℃; for 66.0h;	N,N-Diisopropylethylamine (0.26 mL, 1.505 mmol) was added to 2-chloro-4-((2-fluoro-6-(trifluoromethyl)benzyl)amino)quinazoline-8-carbonitrile 4 (114.6 mg, 0.301 mmol) in 1,4-dioxane (1.4 mL)and dimethyl sulfoxide (1.4 mL) at room temperature, followed by<strong>[1041053-44-4]oxazol-2-ylmethanamine hydrochloride</strong> 5g (61 mg, 0.452 mmol)and the solution was heated to 100 C and stirred for sixty-six hours. The reaction mixture was poured into ether, washed withwater, dried over magnesium sulfate, filtered, and concentrated.The residue was purified by silica gel chromatography, eluting withethyl acetate:hexanes (1:1) to give 4-((2-fluoro-6-(trifluoromethyl)benzyl)amino)-2-((oxazol-2-ylmethyl)amino)quinazoline-8-carbonitrile6g (64.8 mg, 0.111 mmol, 37.0% yield). 1H NMR (400 MHz,CD3SOCD3) d 8.45-8.26 (m, 2H), 8.04-7.84 (m, 2H), 7.72-7.52 (m,4H), 7.16-7.02 (m, 2H), 4.80-4.68 (m, 2H), 4.68-4.54 (m, 2H);LC-MS (LC-ES) M+H = 443.

Reference： [1]Bioorganic and Medicinal Chemistry,2018,vol. 26,p. 2107 - 2150

6
[ 1041053-44-4 ]
[ 157665-52-6 ]
te rt-Butyl 4-nitro-3-[(1,3-oxazol-2-ylmethyl)amino]benzoate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
75%	With potassium carbonate; In N,N-dimethyl-formamide; at 60℃; for 2.0h;	To a suspension of the oxazol-2-ylmethanamine HC1 salt (491 mg, 3.65 mmol) and Intermediate 29 (800 mg, 3.32 mmol) in DMF (5 mE) was added K2C03 (1.04 g, 6.63 mmol). The reaction was stirred at 60 C. for 2 h. Additional oxazol-2-ylmethanamine HC1 salt (100 mg, 1.0 mmol) was added and reaction stirred for an additional 30 mm at 60 C. The reaction was cooled to RT then diluted with water (30 mE) and extracted with EtOAc (60 mE). The organic layer was washed with water, then brine, dried over Na2504, filtered and concentrated under reduced pressure. The orange residue was purified by flash chromatography (12 g silica gel, 0-50% EtOAc/heptane gradient) to deliver teflbutyl 4-nitro-3-((oxazol-2-ylmethyl)amino)benzoate (764 mg, 75%) as an orange solid. ?H NMR (CDC13) oe 8.48 (br s, 1H), 8.23 (d, 1H), 7.68 (d, 1H), 7.61 (d, 1H), 7.28 (dd, 1H), 7.15 (s, 1H), 4.72 (d, 2H), 1.60 (s, 9H).
75%	With potassium carbonate; In N,N-dimethyl-formamide; at 60℃; for 2.5h;	To a suspension of 1 -(1 ,3-oxazol-2-yl)methanamine, hydrochloride salt (491 mg, 3.65 mmol) and fe/f-butyl 3-fluoro-4-nitrobenzoate (800 mg, 3.32 mmol) in A/,A/-dimethylformamide (5 mL) was added potassium carbonate (1 .04 g, 6.63 mmol). The reaction was stirred at 60 C for 2 hours. Additional 1 -(1 ,3-oxazol-2-yl)methanamine, hydrochloride salt (100 mg, 1 .0 mmol) was added and the reaction was stirred for an additional 30 minutes at 60 C. The reaction was cooled to room temperature then diluted with water (30 mL) and extracted with EtOAc (60 mL). The organic layer was washed with water, then saturated aqueous sodium chloride solution, dried over sodium sulfate, filtered and concentrated under reduced pressure. The orange residue was purified by flash chromatography (12 g silica gel, 0-50% EtOAc / heptane gradient) to deliver P25 (764 mg, 75%) as an orange solid. NMR (CDCI3) d 8.48 (br s, 1 H), 8.23 (d, 1 H), 7.68 (d, 1 H), 7.61 (d, 1 H), 7.28 (dd, 1 H), 7.15 (s, 1 H), 4.72 (d, 2H), 1 .60 (s, 9H).

Reference： [1]Patent: US2018/170908,2018,A1 .Location in patent: Paragraph 0480
[2]Patent: WO2019/239371,2019,A1 .Location in patent: Page/Page column 83; 84

7
[ 1041053-44-4 ]
methyl 6-chloro-5-nitropyridine-2-carboxylate [ No CAS ]
methyl 6-[(1,3-oxazol-2-ylmethyl)amino]-5-nitropyridine-2-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With triethylamine; In tetrahydrofuran; at 25℃; for 14.0h;	Triethylamine (532 mg, 5.26 mmol) was added to a suspension of 1-(1,3-oxazol-2-yl)methanamine, hydrochloride salt (236 mg, 1.75 mmol) and methyl 6-chloro-5-nitropyridine-2-carboxylate (386 mg, 1.78 mmol) in tetrahydrofuran (5 mL). After the reaction mixture had been stirred at 25 C. for 14 hours, it was poured into water (30 mL) and extracted with dichloromethane (2×50 mL). The combined organic layers were dried over magnesium sulfate, filtered, and concentrated in vacuo; silica gel chromatography (Gradient: 0% to 5% methanol in dichloromethane) afforded C65 as a yellow solid. Yield: 310 mg, 1.11 mmol, 63%. LCMS m/z 278.7 [M+H]+. 1H NMR (400 MHz, chloroform-d) delta 8.69-8.61 (br m, 1H), 8.58 (d, J=8.4 Hz, 1H), 7.65 (d, J=0.8 Hz, 1H), 7.46 (d, J=8.4 Hz, 1H), 7.11 (d, J=1.0 Hz, 1H), 5.07 (d, J=5.3 Hz, 2H), 3.97 (s, 3H).

Reference： [1]Patent: US2019/382384,2019,A1 .Location in patent: Paragraph 0574; 0575

8
[ 1041053-44-4 ]
C₁₃H₁₁N₅O₃ [ No CAS ]
C₁₇H₁₅N₇O₃ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
22.25%	With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In N,N-dimethyl-formamide at 20℃; for 8h;	49; 61 EXAMPLE 49: SYNTHESIS OF COMPOUND 196 To a mixture of compound 1 (100 mg, 350.56 umol, 1 eq) and compound 2 (56.61 mg, 420.67 umol, 1.2 eq, HCl) in DMF (2 mL) was added DIEA (135.92 mg, 1.05 mmol, 183.18 uL, 3 eq) and HATU (199.94 mg, 525.84 umol, 1.5 eq), the mixture was stirred at 20 °C for 8 hr. LCMS showed desired MS was detected. The reaction mixture was diluted with water (5 mL), extracted with EtOAc (5 mL2), dried over Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (column: Boston Green ODS 15030mm*5um;mobile phase: [water(0.225%FA)-ACN];B%: 10%-40%,10min) to give compound 196 (30 mg, 78.01 umol, 22.25% yield, 95% purity) as yellow solid. 1H NMR (400MHz, DMSO-d6) d = 12.42 (br. s, 1H), 9.52 (t, J = 5.9 Hz, 1H), 8.38 (s, 1H), 8.07 (d, J = 0.8 Hz, 1H), 7.47 - 7.43 (m, 1H), 7.18 (d, J = 0.8 Hz, 1H), 6.83 (br. d, J = 1.9 Hz, 1H), 5.05 (s, 2H), 4.58 (d, J = 6.0 Hz, 2H), 4.28 (br. t, J = 5.6 Hz, 2H), 3.12 (br. t, J = 5.1 Hz, 2H) 13C NMR (101MHz, DMSO-d6) d = 169.09, 160.95, 159.61, 154.38, 140.31, 127.53, 124.09, 111.48, 102.75, 102.64, 43.35, 42.86, 36.58, 23.63. LCMS: Rt=0.700 min, [M+H]+= 366.2

Reference： [1]Current Patent Assignee: INSILICO MEDICINE IP LIMITED - WO2020/198583, 2020, A1 Location in patent: Paragraph 000340; 000371

9
[ 1041053-44-4 ]
[ 69651-48-5 ]
tert-butyl (S)-(1-(4-hydroxyphenyl)-2-((oxazol-2-ylmethyl)amino)-2-oxoethyl)carbamate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
64%	Stage #1: N-tert-butyloxycarbonyl-L-4-hydroxyphenylglycine With 1-hydroxy-7-aza-benzotriazole; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide at 5℃; for 0.166667h; Stage #2: 1-(1,3-oxazol-2-yl)methanamine hydrochloride salt In N,N-dimethyl-formamide at 5 - 20℃; for 2h;	Step 1: tert-butyl (S)-(1-(4-hydroxyphenyl)-2-((oxazol-2-ylmethyl)amino)-2-oxoethyl)carbamate (163d). The title compound (417 mg, 64%) was synthesized from (S)-2-((tert-butoxycarbonyl)amino)-2-(4-hydroxyphenyl)acetic acid 162 (500 mg, 1.87 mmol) and 2-aminomethyl-oxazole hydrochloride (277 mg, 2.06 mmol) according to the same procedure described in step 1 in the preparation of intermediate 163a in the synthesis of compound 92 without further purification. LCMS (ES+) m/z calculated for C17H21N3O5 347.15, found 292 (M+H-tBu)+.
64%	Stage #1: N-tert-butyloxycarbonyl-L-4-hydroxyphenylglycine With 1-hydroxy-7-aza-benzotriazole; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide at 5℃; for 0.166667h; Stage #2: 1-(1,3-oxazol-2-yl)methanamine hydrochloride salt In N,N-dimethyl-formamide at 5 - 20℃; for 2h;	Step 1: tert-butyl (S)-(1-(4-hydroxyphenyl)-2-((oxazol-2-ylmethyl)amino)-2-oxoethyl)carbamate (163d). The title compound (417 mg, 64%) was synthesized from (S)-2-((tert-butoxycarbonyl)amino)-2-(4-hydroxyphenyl)acetic acid 162 (500 mg, 1.87 mmol) and 2-aminomethyl-oxazole hydrochloride (277 mg, 2.06 mmol) according to the same procedure described in step 1 in the preparation of intermediate 163a in the synthesis of compound 92 without further purification. LCMS (ES+) m/z calculated for C17H21N3O5 347.15, found 292 (M+H-tBu)+.

Reference： [1]Abate, Luigi; Amaudrut, Jerome; Beghetto, Elisa; Bianchi, Elisabetta; Bresciani, Alberto; Colarusso, Stefania; Conte, Immacolata; Ferrigno, Federica; Missineo, Antonino; Montalbetti, Christian; Ontoria, Jesus M.; Paonessa, Giacomo; Pavone, Francesca; Ponzi, Simona; Tomei, Licia; Toniatti, Carlo [Bioorganic and Medicinal Chemistry, 2022, vol. 57]
[2]Abate, Luigi; Amaudrut, Jerome; Beghetto, Elisa; Bianchi, Elisabetta; Bresciani, Alberto; Colarusso, Stefania; Conte, Immacolata; Ferrigno, Federica; Missineo, Antonino; Montalbetti, Christian; Ontoria, Jesus M.; Paonessa, Giacomo; Pavone, Francesca; Ponzi, Simona; Tomei, Licia; Toniatti, Carlo [Bioorganic and Medicinal Chemistry, 2022, vol. 57]

Same Skeleton Products

Related Products

Historical Records

Similar Product of
[ 1041053-44-4 ]

A739795[ 885331-17-9 ]

Oxazol-2-ylmethanamine

Reason: Free-salt

Related Functional Groups of
[ 1041053-44-4 ]

Amines

[ 885331-17-9 ]

Oxazol-2-ylmethanamine

Similarity: 0.98

[ 1083299-13-1 ]

N-Methyl-1-(oxazol-2-yl)methanamine

Similarity: 0.93

[ 1391733-72-4 ]

(4-Methyloxazol-2-yl)methanamine hydrochloride

Similarity: 0.85

[ 1398504-16-9 ]

N-(Oxazol-2-ylmethyl)propan-2-amine

Similarity: 0.85

[ 1017228-56-6 ]

(5-Methyloxazol-2-yl)methanamine

Similarity: 0.81

Related Parent Nucleus of
[ 1041053-44-4 ]

Oxazoles

[ 885331-17-9 ]

Oxazol-2-ylmethanamine

Similarity: 0.98

[ 1083299-13-1 ]

N-Methyl-1-(oxazol-2-yl)methanamine

Similarity: 0.93

[ 1391733-72-4 ]

(4-Methyloxazol-2-yl)methanamine hydrochloride

Similarity: 0.85

[ 1398504-16-9 ]

N-(Oxazol-2-ylmethyl)propan-2-amine

Similarity: 0.85

[ 1017228-56-6 ]

(5-Methyloxazol-2-yl)methanamine

Similarity: 0.81

Ghs Precautionary Statements

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]}	{[ getRatePrice(item.pr_usd, 1,1) ]}	{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]}	{[ item.pr_usastock ]}	Inquiry -	{[ item.pr_chinastock ]}	Inquiry -

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

[ CAS No. 1041053-44-4 ]

Quality Control of [ 1041053-44-4 ]

Related Doc. of [ 1041053-44-4 ]

Product Details of [ 1041053-44-4 ]

Calculated chemistry of [ 1041053-44-4 ]

Physicochemical Properties

Pharmacokinetics

Lipophilicity

Druglikeness

Water Solubility

Medicinal Chemistry

Safety of [ 1041053-44-4 ]

Application In Synthesis of [ 1041053-44-4 ]

[ 1041053-44-4 ] Synthesis Path-Downstream 1~9

Similar Product of [ 1041053-44-4 ]

Related Functional Groups of [ 1041053-44-4 ]

Amines

Related Parent Nucleus of [ 1041053-44-4 ]

Oxazoles

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Similar Product of
[ 1041053-44-4 ]

Related Functional Groups of
[ 1041053-44-4 ]

Related Parent Nucleus of
[ 1041053-44-4 ]